Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

Georgi Momekov; Denitsa Momekova

doi:10.1101/2020.04.11.20061804

Article Information

doi

https://doi.org/10.1101/2020.04.11.20061804

History

May 22, 2020.

Article Versions

Version 1 (April 17, 2020 - 05:12).
You are viewing Version 2, the most recent version of this article.

Author Information

Georgi Momekova,* and
Denitsa Momekovab

^aLab of Experimental Chemotherapy and Molecular Pharmacology, Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria
^bDepartment of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

↵*CONTACT: Georgi Momekov, e-mail: gmomekov{at}gmail.com Lab of Experimental Chemotherapy and Molecular Pharmacology, Department of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 2 Dunav Str., 1000 Sofia, Bulgaria

Comments

medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions and read our Comment Policy before commenting. The content of a comment is not endorsed by medRxiv.

View 1 comment on earlier versions of this paper

Community Reviews

medRxiv aims to inform readers about online discussion of this preprint occurring elsewhere. The content at the links below is not endorsed by either medRxiv or the preprint's authors.

Community reviews for this article:

There are no community reviews for this paper.

Automated Evaluations

Certain services provide automated analysis of preprints. Analyses invited by the authors are displayed at the top of this tab. Those done independently of authors are shown underneath . None of these analyses is endorsed by medRxiv.

Automated Evaluations:

There are no automated evaluations for this paper.

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

Article Information

Article Versions

Author Information

Subject Area

Citation Manager Formats

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens

Article Information

Article Versions

Author Information

Subject Area

Follow this preprint